Shh treatment reduced CD5 expression and the CD4/CD8 ratio in thymus explants. (A) CD4 and CD8 profiles of 7-day C57BL/6 E17.5 FTOC control and treated with 0.05 \#956;g/mL r-Shh. The bar chart shows the mean ratio of mature (CD3high) CD4/CD8 SP in 7-day FTOC for Shh\#8722;/\#8722; and C57BL/6 E17.5 cultured with the stated concentration of recombinant Shh (r-Shh). For all treatments, n = 4. Mean cell recovery was as follows: control, 1.87 × 105; 0.5 \#956;g/mL r-Shh, 1.66 × 105; 0.05 \#956;g/mL r-Shh, 2.07 × 105; 0.005 \#956;g/mL r-Shh, 2.1 × 105; and 0.0005 \#956;g/mL r-Shh, 1.54 × 105. (B) CD5 expression on r-Shh\#8211;treated FTOC. Overlaid histograms of CD5 expression gated on the subsets from the FACS plots above for control cultures (gray filled) and r-Shh\#8211;treated cultures (gray line only, no fill). MFIs were (control/+ r-Shh) as follows: DP, 424.5/219.6; CD4SP, 1197.7/586.6; and CD8SP, 425.3/220.8. The bar chart shows MFI for the control (\#9641;) and Shh-treated (\#9633;) cultures. (C) CD4 and CD8 profiles of 10-day C57BL/6 E17.5 FTOC control and treated with 0.5 \#956;g/mL r-Shh. Mean cell recovery was as follows: control, 1.34 × 105; 0.5 \#956;g/mL r-Shh, 1.44 × 105. (D) Profiles of CD4 and CD8, gated on CD3high of 10-day C57BL/6 FTOC control and treated with 0.5 \#956;g/mL r-Shh.